

PRESSURE BIOSCIENCES INC  
Form 10-Q  
November 15, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

**(Mark One)**

**Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the quarterly period ended September 30, 2016

or

**Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-21615

**PRESSURE BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Massachusetts**

(State or other jurisdiction

of incorporation or organization)

**04-2652826**

(I.R.S. Employer

Identification No.)

**14 Norfolk Avenue**

**South Easton, Massachusetts**

(Address of principal executive offices) (Zip Code)

**02375**

**(508) 230-1828**

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).

Yes  No

The number of shares outstanding of the Issuer's common stock as of November 11, 2016 was 30,868,862.

TABLE OF CONTENTS

	Page
<u>PART I - FINANCIAL INFORMATION</u>	
<u>Item 1. Financial Statements</u>	3
<u>Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (Unaudited)</u>	3
<u>Condensed Consolidated Statements of Operations for the Three Months and Nine Months Ended September 30, 2016 and 2015 (Unaudited)</u>	4
<u>Condensed Consolidated Statements of Comprehensive Loss for the Three Months and Nine Months Ended September 30, 2016 and 2015 (Unaudited)</u>	5
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2016 and 2015 (Unaudited)</u>	6
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	7
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	21
<u>Item 3. Quantitative and Qualitative Disclosure About Market Risk</u>	28
<u>Item 4. Controls and Procedures</u>	28
<u>PART II - OTHER INFORMATION</u>	29
<u>Item 1. Legal Proceedings</u>	29
<u>Item 1A. Risk Factors</u>	29
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	29
<u>Item 3. Defaults Upon Senior Securities</u>	29
<u>Item 4. Mine Safety Disclosures</u>	29
<u>Item 5. Other Information</u>	29
<u>Item 6. Exhibits</u>	30
<u>SIGNATURES</u>	31



**PART I - FINANCIAL INFORMATION****Item 1. Financial Statements****PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED BALANCE SHEETS****(UNAUDITED)**

	September 30, 2016	December 31, 2015
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$41,939	\$116,783
Accounts receivable	589,682	113,256
Inventories, net of \$50,000 reserve at September 30, 2016 and December 31, 2015	1,008,138	1,038,371
Prepaid income taxes	7,405	7,381
Prepaid expenses and other current assets	179,954	213,926
Total current assets	1,827,118	1,489,717
Investment in available-for-sale equity securities	59,550	294,522
Property and equipment, net	7,933	20,149
<b>TOTAL ASSETS</b>	<b>\$1,894,601</b>	<b>\$1,804,388</b>
<b>LIABILITIES AND STOCKHOLDERS' DEFICIT</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$532,214	\$941,389
Accrued employee compensation	185,909	176,009
Accrued professional fees and other	690,230	821,088
Deferred revenue	270,102	140,878
Convertible debt, net of unamortized debt discounts of \$1,891,206 at September 30, 2016 and \$0 at December 31, 2015	2,664,334	100,000
Other debt, net of unamortized discounts of \$5,183 and \$3,041, respectively	242,963	151,628
Warrant derivative liability	4,325,864	3,295,976
Conversion option derivative liability	4,627,452	3,940,791
Total current liabilities	13,539,068	9,567,759
<b>LONG TERM LIABILITIES</b>		
Related party convertible debt, net of unamortized debt discounts of \$199,436 and \$0, respectively	91,568	—
Convertible debt, net of unamortized debt discounts of \$2,076,658 and \$5,223,658, respectively	986,843	177,342
Deferred revenue	36,935	36,935

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

TOTAL LIABILITIES	14,654,414	9,782,036
COMMITMENTS AND CONTINGENCIES (Note 5)		
STOCKHOLDERS' DEFICIT		
Series D Convertible Preferred Stock, \$.01 par value; 850 shares authorized; 300 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively (Liquidation value of \$300,000)	3	3
Series G Convertible Preferred Stock, \$.01 par value; 240,000 shares authorized; 86,570 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	866	866
Series H Convertible Preferred Stock, \$.01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	100	100
Series H2 Convertible Preferred Stock, \$.01 par value; 21 shares authorized; 21 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	—	—
Series J Convertible Preferred Stock, \$.01 par value; 6,250 shares authorized; 3,521 and 3,546 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	35	36
Series K Convertible Preferred Stock, \$.01 par value; 15,000 shares authorized; 6,816 and 11,416 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	68	114
Common stock, \$.01 par value; 100,000,000 shares authorized; 30,599,839 and 23,004,898 shares issued and outstanding on September 30, 2016 and December 31, 2015, respectively	305,998	230,050
Warrants to acquire common stock	5,683,897	5,416,681
Additional paid-in capital	27,080,191	26,036,733
Accumulated other comprehensive income	(339,997 )	(105,025 )
Accumulated deficit	(45,490,974)	(39,557,206)
Total stockholders' deficit	(12,759,813)	(7,977,648 )
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$ 1,894,601	\$ 1,804,388

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

**PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(UNAUDITED)**

	<b>For the Three Months Ended</b>		<b>For the Nine Months Ended</b>	
	<b>September 30, 2016</b>	<b>2015</b>	<b>September 30, 2016</b>	<b>2015</b>
Revenue:				
Products, services, other	\$500,949	\$481,452	\$1,429,487	\$1,174,391
Grant revenue	34,385	98,882	127,289	259,181
Total revenue	535,334	580,334	1,556,776	1,433,572
Costs and expenses:				
Cost of products and services	262,894	209,804	727,698	575,780
Research and development	268,317	355,574	925,015	878,899
Selling and marketing	224,380	207,888	609,501	574,289
General and administrative	231,550	497,796	1,853,010	2,034,040
Total operating costs and expenses	987,141	1,271,062	4,115,224	4,063,008
Operating loss	(451,807 )	(690,728 )	(2,558,448 )	(2,629,436 )
Other (expense) income:				
Interest expense, net	(1,116,328 )	(1,584,830 )	(2,961,708 )	(2,831,106 )
Other expense	(200 )	—	(1,112 )	(36,910 )
Gain on extinguishment of embedded derivative liabilities	—	1,180,251	—	2,028,324
Change in fair value of derivative liabilities	623,128	437,379	(412,500 )	38,968
Total other (expense) income	(493,400 )	32,800	(3,375,320 )	(800,724 )
Net loss	(945,207 )	(657,928 )	(5,933,768 )	(3,430,160 )
Accrued dividends on convertible preferred stock	—	1,711	—	(21,768 )
Net loss applicable to common shareholders	\$(945,207 )	\$(656,217 )	\$(5,933,768 )	\$(3,451,928 )
Net loss per share attributable to common stockholders – basic and diluted	\$(0.03 )	\$(0.03 )	\$(0.23 )	\$(0.17 )
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	29,425,362	20,737,827	26,139,740	19,771,323

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements





**PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(UNAUDITED)**

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2016	2015	2016	2015
Comprehensive Loss				
Net loss	\$(945,207)	\$(657,928)	\$(5,933,768)	\$(3,430,160)
Other comprehensive loss				
Unrealized loss on marketable securities	(22,233 )	—	(234,972 )	—
Comprehensive loss	\$(967,440)	\$(657,928)	\$(6,168,740)	\$(3,430,160)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

**PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(UNAUDITED)**

	For the Nine Months Ended September 30,	
	2016	2015
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net loss	\$(5,933,768)	\$(3,430,160)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	15,489	18,279
Accretion of interest and amortization of debt discount	2,848,058	2,367,381
Penalty interest added to debt principal	41,200	-
Gain on settlement of debt	(5,044 )	-
Stock-based compensation expense	282,811	185,370
Amortization of third party fees paid in common stock and warrants	332,700	173,538
Gain on extinguishment of embedded derivative liabilities	-	(2,028,324)
Change in fair value of derivative liabilities	412,500	(38,968 )
Changes in operating assets and liabilities:		
Accounts receivable	(476,426 )	(90,800 )
Inventories	30,233	41,709
Prepaid expenses and other assets	33,948	123,808
Accounts payable	(409,175 )	(200,969 )
Accrued employee compensation	9,900	48,606
Deferred revenue and other accrued expenses	80,058	150,581
Net cash used in operating activities	(2,737,516)	(2,679,949)
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchases of property plant and equipment	(3,273 )	(6,662 )
Net cash used in investing activities	(3,273 )	(6,662 )
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Net proceeds from related party convertible debt	96,667	6,300
Payments on related party debt	-	(12,300 )
Net proceeds from convertible debt	2,102,382	3,991,437
Payments on convertible debt	-	(2,107,065)
Net proceeds from non-convertible debt	865,152	1,300,000
Payments on non-convertible debt	(781,221 )	(537,641 )
Net proceeds from the issuance of common stock	382,965	-
Payment of prepayment penalty	-	(351,193 )
Net cash provided by financing activities	2,665,945	2,289,538
<b>NET DECREASE IN CASH</b>	<b>(74,844 )</b>	<b>(397,073 )</b>

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

CASH AT BEGINNING OF YEAR	116,783	473,948
CASH AT END OF PERIOD	\$41,939	\$76,875
SUPPLEMENTAL INFORMATION		
Interest paid in cash	\$1,154	\$239,389
Income taxes paid in cash	-	-
NON CASH TRANSACTIONS:		
Convertible debt exchanged for common stock	117,837	338,000
Cashless exercise of warrants	11,100	-
Discount due to beneficial conversion feature	20,721	-
Discount due to warrants issued with debt	39,755	-
Common stock issued with debt	104,731	-
Common stock issued to settle non-convertible debt	41,200	-
Conversion of preferred stock into common stock	63,904	-
Extension fees added to principal	-	84,000
Issuance of common stock for investment in available-for-sale equity securities	-	399,547
Accrued dividends on preferred stock	-	21,768
Unrealized loss from available-for-sale equity securities	234,972	76,687
Debt discount from derivative liability	1,304,049	5,085,536
Prepayment penalty and accrued interest enrolled into debt principal	-	48,950

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

**PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2016**

**(UNAUDITED)**

**1) Business Overview, Liquidity and Management Plans**

Pressure BioSciences, Inc. (“we”, “our”, “the Company”) is focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming and, in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking – the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called pressure cycling technology, or PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels i.e., 35,000 pounds per square inch (“*psi*”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“*DNA*”), ribonucleic acid (“*RNA*”), proteins, lipids and small molecules. Our laboratory instrument, the Barocycler<sup>®</sup>, and our internally developed consumables product line, which include our Pressure Used to Lyse Samples for Extraction (“*PULSE*”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up our PCT Sample Preparation System (“*PCT SPS*”).

In 2015, together with an investment bank, we formed a subsidiary called Pressure BioSciences Europe (“PBI Europe”) in Poland. We have 49% ownership interest with the investment bank retaining 51%. As of now, PBI Europe does not have any operating activities but is expected to commence operations in 2017. Therefore, we don’t have control of the subsidiary and did not consolidate in our financial statements.

**2) Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. However, we have experienced negative cash flows from operations with respect to our pressure cycling technology

business since our inception. As of September 30, 2016, we do not have adequate working capital resources to satisfy our current liabilities and as a result, there is substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Note 6, we completed an over-subscribed \$5.0 million debt financing on March 31, 2016 with a total amount raised of \$6.3 million. We have financing efforts in place to continue to raise cash through debt and equity offerings.

Management has developed a plan to continue operations. This plan includes obtaining equity or debt financing. During the nine months ended September 30, 2016 we received \$3,447,166 net proceeds, in additional convertible, non-convertible debt and shares of common stock. Although we have successfully completed financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful.

We need substantial additional capital to fund normal operations in future periods. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects. These financial statements do not include any adjustments that might result from this uncertainty.

### **3) Interim Financial Reporting**

The accompanying unaudited condensed consolidated balance sheet as of December 31, 2015, which was derived from audited financial statements, and the unaudited interim condensed consolidated financial statements of Pressure BioSciences, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles” or “GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all material adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. For further information, refer to the audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K (the “Form 10-K”) for the fiscal year ended December 31, 2015 as filed with the Securities and Exchange Commission on April 5, 2016.

### **4) Summary of Significant Accounting Policies**

#### *Principles of Consolidation*

The condensed consolidated financial statements include the accounts of Pressure BioSciences, Inc., and its wholly-owned subsidiary PBI BioSeq, Inc. All intercompany accounts and transactions have been eliminated in consolidation.

#### *Reclassifications*

Certain amounts in the 2015 consolidated financial statements have been reclassified to conform to the 2016 presentation.

#### *Use of Estimates*

To prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, we are required to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in projecting future cash flows to quantify deferred tax assets, the costs associated

with fulfilling our warranty obligations for the instruments that we sell, and the estimates employed in our calculation of fair value of stock options awarded and warrant derivative liability. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from the estimates and assumptions used.

*Concentrations*

*Credit Risk*

Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.

The following table illustrates the level of concentration as a percentage of total revenues during the three months and nine months ended September 30, 2016 and 2015.

	For the Three Months Ended September 30, 2016		2015	
Top Five Customers	60 %	43 %		
Federal Agencies	9 %	2 %		

	For the Nine Months Ended September 30, 2016		2015	
Top Five Customers	31 %	34 %		
Federal Agencies	3 %	14 %		



Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of September 30, 2016 and December 31, 2015:

	September 30, 2016		December, 31, 2015	
Top Five Customers	55	%	93	%
Federal Agencies	9	%	1	%

*Product Supply*

A Massachusetts-based contract manufacturer started building the new NEP2320 Extreme Barocycler instrument in May 2016. We plan to have this manufacturer build all instruments in the future.

*Investment in Available-For-Sale Equity Securities*

As of September 30, 2016, we held 601,500 shares of common stock of Everest Investments Holdings S.A. (“Everest”), a Polish publicly traded company listed on the Warsaw Stock Exchange. We account for this investment in accordance with ASC 320 “*Investments — Debt and Equity Securities*” as securities available for sale. On September 30, 2016, our condensed consolidated balance sheet reflected the fair value of our investment in Everest to be \$59,550, based on the closing price of Everest shares of \$0.10 per share on that day. The carrying value of our investment in Everest common stock held will change from period to period based on the closing price of the common stock of Everest as of the balance sheet date. This change in market value will be recorded by us on a quarterly basis as an unrealized gain or loss in Comprehensive Income or Loss.

*Inventories*

Inventories are valued at the lower of cost (average cost) or market (sales price). The cost of Barocyclers consists of the cost charged by the contract manufacturer. The cost of manufactured goods includes material, freight-in, direct labor, and applicable overhead. The composition of inventory is as follows:

	September 30, 2016	December 31, 2015
Raw materials	\$491,254	\$310,367
Finished goods	566,884	778,004
Inventory Reserve	(50,000 )	(50,000 )
Total	\$1,008,138	\$1,038,371

*Debt Issuance Costs*

In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs be presented as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as deferred charge assets, separate from the related debt liability. ASU 2015-03 does not change the recognition and measurement requirements for debt issuance costs. The Company early-adopted ASU 2015-03 as of the end of its Fiscal 2015, and applied its provisions retrospectively.

*Computation of Loss per Share*

Basic loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed by dividing loss available to common shareholders by the weighted average number of common shares outstanding plus additional common shares that would have been outstanding if dilutive potential common shares had been issued. For purposes of this calculation, convertible preferred stock, common stock dividends, and warrants and options to acquire common stock, are all considered common stock equivalents in periods in which they have a dilutive effect and are excluded from this calculation in periods in which these are anti-dilutive to our net loss.

The following table illustrates our computation of loss per share for the three months and nine months ended September 30, 2016 and 2015:

	For the Three Months Ended September 30, 2016		For the Nine Months Ended September 30, 2015	
Numerator:				
Net loss	\$ (945,207 )	\$ (657,928 )	\$ (5,933,768 )	\$ (3,430,160 )
Preferred dividends accrued	—	1,711	—	(21,768 )
Net loss applicable to common shareholders	\$ (945,207 )	\$ (656,217 )	\$ (5,933,768 )	\$ (3,451,928 )
Denominator for basic and diluted loss per share:				
Weighted average common stock shares outstanding	29,425,362	20,737,827	26,139,740	19,771,323
Income (loss) per common share – basic and diluted	\$ (0.03 )	\$ (0.03 )	\$ (0.23 )	\$ (0.17 )

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series J Convertible Preferred Stock and Series K Convertible Preferred Stock are presented below as if they were converted into common shares according to the conversion terms.

	As of September 30,	
	2016	2015
Stock options	5,269,250	3,201,250
Convertible debt	26,971,732	26,015,029
Common stock warrants	24,824,695	26,125,127
Convertible preferred stock:		
Series D Convertible Preferred Stock	750,000	750,000
Series G Convertible Preferred Stock	865,700	865,700
Series H Convertible Preferred Stock	1,000,000	1,000,000
Series H2 Convertible Preferred Stock	2,100,000	2,100,000
Series J Convertible Preferred Stock	3,521,000	3,546,000
Series K Convertible Preferred Stock	6,816,000	11,399,000
	72,118,377	75,002,106

#### *Accounting for Stock-Based Compensation Expense*

We maintain equity compensation plans under which incentive stock options and non-qualified stock options are granted to employees, independent members of our Board of Directors and outside consultants. We recognize stock-based compensation expense over the requisite service period using the Black-Scholes formula to estimate the fair value of the stock options on the date of grant.

#### Determining Fair Value of Stock Option Grants

**Valuation and Amortization Method** - The fair value of each option award is estimated on the date of grant using the Black-Scholes pricing model based on certain assumptions. The estimated fair value of employee stock options is amortized to expense using the straight-line method over the vesting period.

**Expected Term** - The Company uses the simplified calculation of expected life, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected term. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

Expected Volatility - Expected volatility is based on the Company's historical stock volatility data over the expected term of the award.

Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. The Company estimated a forfeiture rate of 5% for awards granted based on historical experience and future expectations of options vesting. The Company used this historical rate as our assumption in calculating future stock-based compensation expense.

The Company recognized stock-based compensation expense of \$90,500 and \$74,864 for the three months ended September 30, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations:

	For the Three Months Ended September 30,	
	2016	2015
Research and development	\$ 14,735	\$ 18,307
Selling and marketing	9,911	13,310
General and administrative	65,854	43,247
Total stock-based compensation expense	\$ 90,500	\$ 74,864

The Company recognized stock-based compensation expense of \$282,811 and \$185,370 for the nine months ended September 30, 2016 and 2015, respectively. The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Condensed Consolidated Statements of Operations:

	For the Nine Months Ended September 30	
	2016	2015
Research and development	\$ 50,766	\$ 41,172
Selling and marketing	32,404	27,386
General and administrative	199,641	116,812
Total stock-based compensation expense	\$ 282,811	\$ 185,370

#### *Fair Value of Financial Instruments*

Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their fair value. Long-term liabilities are primarily related to convertible debentures and deferred revenue with carrying values that approximate fair value.

#### *Fair Value Measurements*

The Company follows the guidance of FASB ASC Topic 820, “*Fair Value Measurements and Disclosures*” (“ASC 820”) as it related to all financial assets and financial liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis.

The Company generally defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company uses a three-tier fair value hierarchy, which classifies the inputs used in measuring fair values. These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the Company to develop its own assumptions.

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company has determined that its financial assets are classified within Level 1 and its financial liabilities are currently classified within Level 3 in the fair value hierarchy. The development of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's management.

The following tables set forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2016:

	Fair value measurements at September 30, 2016 using:			
	September 30, 2016	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Available-For-Sale Equity Securities	\$ 59,550	\$59,550	\$ -	\$ -
Total Financial Assets	\$ 59,550	\$59,550	\$ -	\$ -

	September 30, 2016	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Series D Preferred Stock Purchase Warrants	\$ 189,884	\$ —	\$ —	\$ 189,884
Warrants Issued with Convertible Debt	4,135,980	—	—	4,135,980
Conversion Option Derivative Liabilities	4,627,452	—	—	4,627,452
Total Derivatives	\$8,953,316	\$ —	\$ —	\$ 8,953,316

The following table provides a summary of the changes in fair value, including net transfers in and/or out, of the derivative financial instruments, measured at fair value on a recurring basis using significant unobservable inputs for the nine months ended September 30, 2016:

	December 31, 2015	Issuance fair value	Change in fair value	Gain on extinguishment of derivative liabilities	September 30, 2016
Available-For-Sale Equity Securities	\$294,522	\$ -	\$(234,972)	\$ —	\$ 59,550



Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

Total Financial Assets                      \$294,522    \$ —    \$(234,972)    \$ —    \$ 59,550

	December 31, 2015	Issuance fair value	Change in fair value	September 30, 2016
Series D Preferred Stock Purchase Warrants	\$173,526	\$—	\$16,358	\$189,884
Convertible Debt Warrants	3,122,450	1,094,432	(80,902 )	4,135,980
Conversion Option Liabilities	3,940,791	1,547,127	(860,466)	4,627,452
Total Derivatives	\$7,236,767	\$2,641,559	\$(925,010)	\$8,953,316

The amounts above valued at issuance includes \$1,337,510 that was charged directly to “change in fair value of derivative liabilities” at issuance.

The following tables set forth the Company's financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2015:

	Fair value measurements at December 31, 2015 using:			
	December 31, 2015	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Available-For-Sale Equity Securities	\$ 294,522	\$ 294,522	\$ —	\$ —
Total Financial Assets	\$ 294,522	\$ 294,522	\$ —	\$ —

	December 31, 2015	Quoted prices in active markets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Series D Preferred Stock Purchase Warrants	\$ 173,526	\$ —	\$ —	\$ 173,526
Warrants Issued with Convertible Debt	3,122,450	—	—	3,122,450
Conversion Option Derivative Liabilities	3,940,791	—	—	3,940,791
Total Derivatives	\$ 7,236,767	\$ —	\$ —	\$ 7,236,767

The assumptions for the binomial pricing model are represented in the table below for the warrants issued in the Series D private placement reflected on a per share common stock equivalent basis.

Assumptions	November 10, 2011	Warrants revalued at December 31, 2015	Warrants revalued at September 30, 2016
Expected life (in months)	60.0	11.0	8.0
Expected volatility	104.5 %	104.9 %	92.4 %
Risk-free interest rate	0.875 %	0.65 %	0.45 %
Exercise price	\$ 0.81	\$ 0.25	\$ 0.25
Fair value per warrant	\$ 0.54	\$ 0.16	\$ 0.18

The assumptions for the binomial pricing model are represented in the table below for the warrants issued with the Convertible Debt throughout the period reflected on a per share common stock equivalent basis.

Assumptions	At Issuance Fair value	Warrants revalued at December 31, 2015	Warrants revalued at September 30, 2016
Expected life (in months)	36.0-60.0	55.0-60.0	46.0-54.0
Expected volatility	114.3 - 138.3 %	136.3-141.6 %	116.2 -137.4 %
Risk-free interest rate	0.86-1.69 %	1.29-1.76 %	1.01 %
Exercise price	\$0.40-\$0.42	0.40	\$0.40
Fair value per warrant	\$0.19-\$0.40	0.30	\$0.30-\$1.35

The assumptions for the binomial pricing model are represented in the table below for the conversion options reflected on a per share common stock equivalent basis.

Assumptions	At Issuance fair value	Conversion options revalued at December 31, 2015	Conversion options revalued at September 30, 2016
Expected life (in months)	3-24	18-24	10-18
Expected volatility	97.6-153.8 %	112.2-114.7 %	94.3%-96.6 %
Risk-free interest rate	0.37-0.99 %	1.06 %	0.59-0.77 %
Exercise price	\$0.24-\$0.45	\$0.28	\$0.28
Fair value per conversion option	\$0.07-\$0.30	\$0.14-\$0.33	\$0.17-\$0.21



## **5) Commitments and Contingencies**

### *Operating Leases*

Our corporate offices are currently located at 14 Norfolk Avenue, South Easton, Massachusetts 02375. We are currently paying \$4,800 per month, on a lease extension, signed on December 29, 2015, that expires December 31, 2016, for our corporate office.

On November 1, 2014 we signed a lease for lab space in Medford, MA. We subsequently expanded our space in Medford. The lease expires December 30, 2017 and requires monthly payments of \$5,385 subject to annual cost of living increases.

Rental costs are expensed as incurred. During the nine months ended September 30, 2016 and 2015 we incurred \$108,038 and \$73,775 in rent expense, respectively for the use of our corporate office and research and development facilities.

### *Government Grants*

We have received a \$1.05 million NIH SBIR Phase II Grant. Under the grant, the NIH has committed to pay the Company to develop a high-throughput, high pressure-based DNA Shearing System for Next Generation Sequencing and other genomic applications. The grant terminates in November 2017.

## **6) Convertible Debt and Other Debt**

### *Senior Secured Convertible Debentures and Warrants*

We entered into Subscription Agreements (the "Subscription Agreement") with various individuals (each, a "Purchaser") between July 23, 2015 and March 31, 2016, pursuant to which the Company sold Senior Secured Convertible Debentures (the "Debentures") and warrants to purchase shares of common stock equal to 50% of the number of shares issuable pursuant to the subscription amount (the "Warrants") for an aggregate purchase price of \$6,329,549 (the "Purchase Price").

The Company issued a principal aggregate amount of \$6,962,504 in Debentures which includes a 10% original issue discount on the Purchase Price. The Debenture does not accrue any additional interest during the first year it is outstanding but accrues interest at a rate equal to 10% per annum for the second year it is outstanding. The Debenture has a maturity date of two years from issuance. The Debenture is convertible any time after its issuance date. The Purchaser has the right to convert the Debenture into shares of the Company's common stock at a fixed conversion price equal to \$0.28 per share, subject to applicable adjustments. In the second year that the Debenture is outstanding, any interest accrued shall be payable quarterly in either cash or common stock, at the Company's discretion.

At any time after the Issuance Date, the Company has the option, subject to certain conditions, to redeem some or all of the then outstanding principal amount of the Debenture for cash in an amount equal to the sum of (i) 120% of the then outstanding principal amount of the Debenture, (ii) accrued but unpaid interest and (iii) any liquidated damages and other amounts due in respect of the Debenture.

The Company issued warrants exercisable into a total of 11,302,766 shares of our common stock. The Warrants issued in this transaction are immediately exercisable at an exercise price of \$0.40 per share, subject to applicable adjustments including full ratchet anti-dilution in the event that we issue any securities at a price lower than the exercise price then in effect. The Warrants have an expiration period of five years from the original issue date. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations and also include anti-dilution price protection for subsequent equity sales below the exercise price.

Subject to the terms and conditions of the Warrants, at any time commencing six months from the Final Closing, the Company has the right to call the Warrants for cancellation if the volume weighted average price of its Common Stock on the OTC QB Market (or other primary trading market or exchange on which the Common Stock is then traded) equals or exceeds three times the per share exercise price of the Warrants for 15 out of 20 consecutive trading days.

In connection with the Subscription Agreement and Debenture, the Company entered into Security Agreements with the Purchasers whereby the Company agreed to grant to Purchasers an unconditional and continuing, first priority security interest in all of the assets and property of the Company to secure the prompt payment, performance and discharge in full of all of Company's obligations under the Debentures, Warrants and the other Transaction Documents.

The Company determined that the conversion feature of the Debentures met the definition of a liability in accordance with ASC 815-40 and therefore bifurcated the conversion feature on each debt agreement and accounted for it as a derivative liability. The fair value of the conversion feature was accounted for as a note discount and are amortized to interest expense over the life of the loan. The fair value of the conversion feature was reflected in the conversion option liability line in the condensed consolidated balance sheets.

The proceeds from these convertible debts were allocated between the host debt instrument and the convertible option based on the residual method. The estimated fair value of the convertible option was determined using a binomial formula, resulting in allocations to the convertible option and accounted for as a liability in the Company's condensed consolidated balance sheet. In accordance with the provisions of ASC 815-40, the gross proceeds are offset by debt discounts, which are amortized to interest expense over the expected life of the debt.

ASC 470-20 states that the proceeds from the issuance of debt with detachable stock warrants should be allocated between the debt and warrants on the basis of their relative fair market values. The debt discount will be amortized to interest expense over the two year term of these loans. We amortized \$2,768,527 of the debt discount to interest expense in 2016. The warrants issued in connection with the convertible debentures are classified as warrant derivative liabilities because the warrants are entitled to certain rights in subsequent financings and the warrants contain "down-round protection" and therefore, do not meet the scope exception for treatment as a derivative under ASC 815, Derivatives and Hedging, ("ASC 815"). Since "down-round protection" is not an input into the calculation of the fair

value of the warrants, the warrants cannot be considered indexed to the Company's own stock which is a requirement for the scope exception as outlined under ASC 815. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of \$2,847,624 to the total warrants out of the gross proceeds of \$6,329,549. The fair value will be affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. We will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability, whichever comes first.



*Other convertible notes*

On May 13, 2016, one lender converted an outstanding note issued on April 28, 2015 and the related accrued interest totaling \$117,837 to 420,849 common shares. As of September 30, 2016, the outstanding balance on the note was zero.

On May 24, we sold an additional convertible note for \$107,000 with warrants to purchase 50,000 shares of common stock at an exercise price of \$0.55 per share. The purchaser has the right to convert the notes into shares of the Company's common stock at a fixed conversion price equal to \$0.45 per share, subject to applicable adjustments. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of \$12,406 to the total warrants and the recognition of a beneficial conversion feature of \$7,962, both of which were recorded as a discount to the note. We evaluated the convertible note and warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment.

On June 14, 2016, we sold an additional convertible note for \$115,000 and issued 30,667 common shares to compensate the lender. On July 1, 2016, the note was modified to increase the principal amount to \$200,000 and we received the remaining proceeds of \$85,000 on the same date and issued 34,333 common shares as compensation to the lender. The lender has the right to convert the note into shares of the Company's common stock at fixed conversion price equal to \$0.45 per share, subject to applicable adjustments. We valued the total 65,000 common shares using the stock prices at the respective dates the note proceeds were received and recorded the relative fair value of the shares amounting to \$26,000 as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financing. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment.

On July 29, 2016, we sold an additional convertible note for \$100,000 and issued 32,500 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company's common stock at a fixed conversion price equal to \$0.45 per share, subject to applicable adjustments. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair values of the convertible note and the common shares was \$87,241 and \$12,759, respectively. We then computed the effective conversion price of the note, noting that the convertible debt gave rise to a beneficial conversion feature (BCF) of \$12,759. The sum of the relative fair value of the common shares and the BCF of \$25,518 was recorded as a debt discount to be amortized over the term of the loan. We also evaluated the convertible note for derivative liability treatment and determined that the instruments does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangements did not qualify for derivative accounting treatment.

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

On September 15, 2016, we sold an additional convertible note for \$500,000 and issued 200,000 common shares to compensate the lender. The lender has the right to convert the notes into shares of the Company's common stock at a fixed conversion price equal to \$0.45 per share, subject to applicable adjustments. The convertible note includes an original issue discount of \$40,541 and is subject to annual interest of 9%. The proceeds were allocated between the convertible note and shares of common stock based on their relative fair values. The relative fair value of the convertible note was \$434,028. The allocation of the gross proceeds to the shares of common stock was \$65,972 and recorded as a debt discount to be amortized over the term of the loan. We then computed the effective conversion price of the note, noting that no beneficial conversion feature exists. We also evaluated the convertible note for derivative liability treatment and determined that the instrument does not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that this financing arrangement did not qualify for derivative accounting treatment.

The specific terms of the convertible debts and outstanding balances as of September 30, 2016 are listed in the table below.

**Fixed Rate Convertible Notes**

<b>Inception Date</b>	<b>Term</b>	<b>Loan Amount</b>	<b>Outstanding Balance</b>	<b>Original Issue Discount</b>	<b>Interest Rate</b>	<b>Deferred Finance Fees</b>	<b>Discount related to fair value of conversion feature and warrants/shares</b>
July 22, 2015	24 months	\$2,180,000	\$ 2,180,000	\$ 218,000	1 10 % <sup>2</sup>	\$ 388,532	\$ 2,163,074
September 25, 2015	24 months	1,100,000	1,100,000	110,000	1 10 % <sup>2</sup>	185,956	1,022,052
October 2, 2015	24 months	150,000	150,000	15,000	1 10 % <sup>2</sup>	26,345	140,832
October 6, 2015	24 months	30,000	30,000	3,000	1 10 % <sup>2</sup>	5,168	26,721
October 14, 2015	24 months	50,000	50,000	5,000	1 10 % <sup>2</sup>	8,954	49,377
November 2, 2015	24 months	250,000	250,000	25,000	1 10 % <sup>2</sup>	43,079	222,723
November 10, 2015	24 months	50,000	50,000	5,000	1 10 % <sup>2</sup>	8,790	46,984
November 12, 2015	24 months	215,000	215,000	21,500	1 10 % <sup>2</sup>	38,518	212,399
November 20, 2015	24 months	200,000	200,000	20,000	1 10 % <sup>2</sup>	37,185	200,000
December 4, 2015	24 months	170,000	170,000	17,000	1 10 % <sup>2</sup>	37,352	170,000
December 11, 2015	24 months	360,000	360,000	36,000	1 10 % <sup>2</sup>	75,449	360,000
December 18, 2015	24 months	55,000	55,000	5,500	1 10 % <sup>2</sup>	11,714	55,000
December 31, 2015	24 months	100,000	100,000	10,000	1 10 % <sup>2</sup>	20,634	100,000
January 11, 2016	24 months	100,000	100,000	10,000	1 10 % <sup>2</sup>	24,966	80,034
January 20, 2016	24 months	50,000	50,000	5,000	1 10 % <sup>2</sup>	9,812	40,188
January 29, 2016	24 months	300,000	300,000	30,000	1 10 % <sup>2</sup>	60,887	239,113
February 26, 2016	24 months	200,000	200,000	20,000	1 10 % <sup>2</sup>	43,952	156,048
March 10, 2016	24 months	125,000	125,000	12,500	1 10 % <sup>2</sup>	18,260	106,740
March 18, 2016	24 months	360,000	360,000	36,000	1 10 % <sup>2</sup>	94,992	265,008
March 24, 2016	24 months	106,667	106,667	10,667	1 10 % <sup>2</sup>	15,427	91,240

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

March 31, 2016	24 months	167,882	167,882	16,788	<sup>1</sup>	10	% <sup>2</sup>	2,436	165,446
April 5, 2016	24 months	10,000	10,000	1,000	<sup>1</sup>	10	% <sup>2</sup>	-	10,000
May 24, 2016	7 months	100,000	100,000	7,000		0	%	-	20,368
June 15, 2016	6 months	40,000	40,000	-		12	%	-	3,680
June 17, 2016	6 months	40,000	40,000	-		12	%	-	3,899
June 22, 2016	6 months	35,000	35,000	-		12	%	-	3,373
July 6, 2016	6 months	85,000	85,000	-		12	%	-	15,048
July 29, 2016	6 months	100,000	100,000	-		12	%	-	25,518
September 15, 2016	8 months	500,000	500,000	40,541		9	%	-	65,972
		\$7,229,549	\$7,229,549	\$680,496				\$1,158,408	\$6,060,837

<sup>1</sup> The original issue discount is reflected in the first year.

<sup>2</sup> The annual interest starts accruing in the second year.

The closings above on March 10, 24, and 31, 2016 included \$264,667 of proceeds received from related parties.

At any time after six months from the Inception Date, the Company has the right to prepay the above Debentures in cash for 120% of the principal amount outstanding and any accrued interest. As of September 30, 2016, a total of approximately \$291,000 convertible debentures were purchased by related parties who were members of the Company's Board of Directors.

The following table provides a summary of the changes in convertible debt, net of unamortized discount, during 2016:

	<b>2016</b>
Balance at January 1,	\$277,342
Issuance of convertible debt, face value	2,509,045
Original issue discount	(189,496 )
Debt discount from derivative liabilities (embedded conversion option and warrants)	(1,153,817)
Debt discount from shares and warrants issued with the notes	(117,137 )
Debt discount from beneficial conversion feature	(20,721 )
Deferred financing fees	(270,732 )
Conversion of debentures to common shares	(100,000)
Accretion of interest and amortization of debt discount to interest expense through September 30,	2,808,261
Balance at September 30,	3,742,745
Less: current portion	2,664,334
Convertible debt, long-term portion	\$1,078,411

#### *Other Notes*

On January 6, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received \$250,000 in exchange for rights to all customer receipts until the lender is paid \$322,500, which is collected at the rate of \$1,280 per business day. The payments were secured by second position rights to all customer receipts until the loan has been paid in full. \$138,840 of the proceeds were used to pay off the outstanding balance of a previous loan from another lender. The Company recognized a gain on the settlement of the previous loan of \$5,044 which was credited to interest expense. The Company paid \$2,500 in fees in connection with this loan. We received an additional \$93,161 in June 2016 under the existing Merchant Agreement. The note was still outstanding as of September 30, 2016 with a balance of \$105,125.

On January 20, 2016, we borrowed \$50,000 from an individual with no interest or fees. We paid back the loan in March 2016.

On February 8, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received \$100,000 in exchange for third position rights to all customer receipts until the lender is paid \$129,900, which is collected at the rate of \$927 per business day. The Company paid \$2,000 in fees in connection with this loan. We received an additional \$125,000 in June 2016 under the existing Merchant Agreement of which \$48,420 was used to pay off the prior loan. The note was still outstanding as of September 30, 2016 with a balance of \$2,119 after payments of \$56,841. The lender provided an additional \$70,000 on August 16, 2016. We repaid a portion of the \$70,000 with \$49,200 remaining as outstanding as of September 30, 2016.

On May 9, 2016 we signed a promissory note with a lender. Under the agreement we received \$200,000 net of a \$6,000 original issue discount and we repaid \$206,000 on August 25, 2016. In connection with this promissory note, we issued warrants exercisable into 100,000 shares of our common stock. The warrants issued in this transaction are immediately exercisable at an exercise price of \$0.55 per share. The warrants have an expiration period of three years from the original issue date. The warrants are subject to adjustment for stock splits, stock dividends or recapitalizations. The warrants were recorded as a component of our Stockholders' Equity. The estimated fair value of the warrants was determined using the binomial model, resulting in an allocation of \$27,349 to the total warrants and recorded as a discount to the note to be amortized over the term of the loan. We evaluated the warrants for derivative liability treatment and determined that these instruments do not include certain rights such as price protection like our previous debt financings. Accordingly, we concluded that these instruments did not qualify for derivative accounting treatment. In August 2016, the lender extended the maturity date of the note from August 11, 2016 to August 25, 2016. Consequently, a penalty interest of \$41,200 was added to the principal amount and settled through the issuance of 100,049 common shares. As of September 30, 2016, the outstanding balance on this note was zero.

On August 26, 2016 we signed a Merchant Agreement with a lender. Under the agreement we received \$122,465 net proceeds in exchange for rights to all customer receipts which is collected at the rate of \$1,386 per business day. The note was still outstanding as of September 30, 2016 with a balance of \$91,736.

## **7) Stockholders' Deficit**

### *Preferred Stock*

We are authorized to issue 1,000,000 shares of preferred stock with a par value of \$0.01. Of the 1,000,000 shares of preferred stock:

- 1) 20,000 shares have been designated as Series A Junior Participating Preferred Stock ("*Junior A*")
- 2) 313,960 shares have been designated as Series A Convertible Preferred Stock ("*Series A*")
- 3) 279,256 shares have been designated as Series B Convertible Preferred Stock ("*Series B*")
- 4) 88,098 shares have been designated as Series C Convertible Preferred Stock ("*Series C*")
- 5) 850 shares have been designated as Series D Convertible Preferred Stock ("*Series D*")
- 6) 500 shares have been designated as Series E Convertible Preferred Stock ("*Series E*")
- 7) 240,000 shares have been designated as Series G Convertible Preferred Stock ("*Series G*")
- 8) 10,000 shares have been designated as Series H Convertible Preferred Stock ("*Series H*")
- 9) 21 shares have been designated as Series H2 Convertible Preferred Stock ("*Series H2*")

10) 6,250 shares have been designated as Series J Convertible Preferred Stock (“*Series J*”)

11) 15,000 shares have been designated as Series K Convertible Preferred Stock (“*Series K*”)

As of September 30, 2016, there were no shares of Junior A, and Series A, B, C and E issued and outstanding. See our Annual Report on Form 10-K for the year ended December 31, 2015 for the pertinent disclosures of preferred stock.

Stock Options and Warrants

Our stockholders approved our amended 2005 Equity Incentive Plan (the “Plan”) pursuant to which an aggregate of 1,800,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards made under the Plan. Under the Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2016, options to acquire 1,153,750 shares were outstanding under the Plan with 646,250 shares available for future grant under the Plan.

On December 12, 2013 at the Company’s special meeting the shareholders approved the 2013 Equity Incentive Plan (the “2013 Plan”) pursuant to which 3,000,000 shares of our common stock were reserved for issuance upon exercise of stock options or other equity awards. Under the 2013 Plan, we may award stock options, shares of common stock, and other equity interests in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2016, a total of 2,047,500 options have been granted under the 2013 Plan with 952,500 shares available for future grants.

On November 29, 2015 the Company’s Board of Directors adopted the 2015 Nonqualified Stock Option Plan (the “2015 Plan”) pursuant to which 5,000,000 shares of our common stock were reserved for issuance upon exercise of non-qualified stock options. Under the 2015 Plan, we may award non-qualified stock options in the Company to employees, officers, directors, consultants, and advisors, and to any other persons the Board of Directors deems appropriate. As of September 30, 2016, non-qualified options to acquire 2,068,000 shares were outstanding under the Plan with 2,932,000 shares available for future grants.

All of the outstanding non-qualified options had an exercise price that was at or above the Company’s common stock share price on September 30, 2016.

The following tables summarize information concerning options and warrants outstanding and exercisable:

	Stock Options Weighted Average	Price	Warrants Weighted Average	Price	Total	
	Shares	per share	Shares	per share	Shares	Exercisable
Balance outstanding, 01/01/15	3,406,250	\$0.51	19,182,201	\$0.49	22,588,451	16,611,528
Granted	2,500,000	0.40	10,837,141	0.40	13,337,141	

Edgar Filing: PRESSURE BIOSCIENCES INC - Form 10-Q

Exercised	—		—		—	
Expired	(205,000 )	1.00	(791,678 )	0.31	(996,678 )	
Forfeited	(130,000 )	0.70	—	—	(130,000 )	
Balance outstanding, 12/31/15	5,571,250	\$0.44	29,227,664	\$0.44	34,798,914	31,664,469
Granted	—	—	4,294,552	0.43	4,294,552	
Exercised	—		(70,000 )	0.31	(70,000 )	
Expired	(186,000 )	1.00	(8,627,521 )	0.61	(8,813,521 )	
Forfeited	(116,000 )	0.51	—	—	(116,000 )	
Balance outstanding, 9/30/2016	5,269,250	\$0.42	24,824,695	\$0.39	30,093,945	28,095,959



Range of Exercise Prices	Options Outstanding			Options Exercisable		
	Number of Options	Weighted Average Remaining Contractual Life (Years)	Exercise Price	Number of Options	Weighted Average Remaining Contractual Life (Years)	Exercise Price
\$0.30 - \$0.39	1,625,500	8.0	\$ 0.30	1,248,514	8.0	\$ 0.30
0.40 - 0.49	2,786,000	9.0	0.40	1,165,000	8.6	0.40
0.50 - 0.59	226,250	5.9	0.50	226,250	5.9	0.50
0.60 - 0.69	385,500	3.4	0.60	385,500	3.4	0.60
0.70 - 1.25	246,000	2.6	1.00	246,000	2.6	1.00
\$0.30 - \$1.25	5,269,250	7.8	\$ 0.42	3,271,264	7.1	\$ 0.44

As of September 30, 2016, the total estimated fair value of unvested stock options to be amortized over their remaining vesting period was \$459,724. The non-cash, stock-based compensation expense associated with the vesting of these options is expected to be \$90,445 for the remainder of 2016, \$212,957 in 2017 and \$156,322 in 2018.

#### Common Stock Issuances

On April 22, 2016, we issued 22,996 shares of common stock in connection with a cashless exercise of 70,000 warrants.

On May 6, 2016, all remaining Series K preferred shareholders except one converted 4,600 shares of preferred stock into approximately 4.6 million shares of the Company's common stock. The Company issued 247,435 shares of common stock to pay the accrued dividend of \$63,413 on Series K preferred stock.

On May 13, 2016, we issued 420,849 shares of common stock to convert \$117,837 of convertible note principal and related interest. See Note 6

On various dates from January to September 2016, we issued a total of 297,500 shares of common stock in connection with the convertible notes issued to lenders. We also issued 100,049 shares of common stock to settle debt of \$41,200. See Note 6.

On August 29, 2016, a Series J preferred shareholder converted 25 shares of preferred stock into 25,000 shares of the Company's common stock. The Company issued 1,112 shares of common stock to pay the accrued dividend of \$445 on Series J preferred stock.

On various dates from January to September 2016 the Company issued 755,000 shares of restricted common stock to investor relations firms for services rendered.

### Sale of Common Stock

On August 29, September 9 and September 14, 2016, we completed private placements, pursuant to which we sold an aggregate of 1,125,000 shares of common stock, \$0.01 par value, for a purchase price of \$0.40 per share, resulting in gross proceeds to us of approximately \$450,000. The shares were issued and sold to a total of 2 accredited investors pursuant to a securities purchase agreement entered into as of August 29, 2016. The investors received warrants to purchase 1,125,000 shares of the Company's common stock at \$0.50 exercise price. The warrants expire 5 years after issuance. We also incurred stock issuance costs related to broker and legal fees of \$67,035 which were charged to additional paid in capital.

### **8) Subsequent Events**

On October 11 and November 10, 2016, we completed two additional tranches of the Fall 2016 Private Placement, pursuant to which we sold an aggregate of 400,000 shares of common stock, \$0.01 par value, for a purchase price of \$0.40 per share, resulting in gross proceeds to us of approximately \$160,000. The Shares were issued and sold to a total of 2 accredited investors pursuant to a Securities Purchase Agreement entered into as of the date of their investments. The investors received warrants to purchase a total of 400,000 shares of the Company's common stock at an exercise price of \$0.50. The warrants expire 5 years after issuance.

On October 28, 2016, an accredited investor (the "Investor") purchased a promissory note in the aggregate principal amount of up to \$2,000,000 (the "Note") due and payable on the earlier of October 28, 2017 or on the seventh business day after the closing of a Qualified Offering (as defined in the Note). Although the Note is dated October 26, 2016, the transaction did not close until October 28, 2016, when the Company received its initial \$250,000 advance pursuant to the Note. As a result, on the same day and pursuant to the Note, the Company issued to the Investor a Common Stock Purchase Warrant to purchase 625,000 shares of the Company's common stock ("Common Stock") at an exercise price per share equal to \$0.40 per share. The Investor is obligated to provide the Company \$250,000 advances under the Note, but the Investor shall not be required to advance more than \$250,000 in any individual fifteen (15) day period and no more than \$500,000 in the thirty (30) day period immediately following the date of the initial advance. Notwithstanding the fifteen (15) day period limitation, on November 2, 2016, the Company received a second \$250,000 advance pursuant to the Note and the Company issued to the Investor the second warrant to purchase 625,000 shares of the Common Stock. The terms of the first and second warrants are identical except for the exercise date, issue date, and termination date. Interest on the principal balance of the Note shall be paid in full on the Maturity Date, unless otherwise paid prior to the Maturity Date. Interest shall be assessed as follows: (i) 10% on all principal amounts advanced prior to April 28, 2017; (ii) the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between April 28, 2017 and July 28, 2017; or (iii) both of the foregoing and 4% on any amount remaining outstanding if the principal amount is repaid between July 28, 2017 and October 28, 2017. Our placement agent is being paid eight percent (8%) of all principal amounts advanced in connection with this

transaction.

On November 1, 2016, we signed a consulting agreement with an investor relations firm for a twelve month period with a six-month cancellation clause. In connection with this agreement, we issued a warrant exercisable at \$0.40 per share for 660,000 shares of our common stock. Of these shares, 330,000 vest immediately and 330,000 shares vest 181 days after November 1, 2016. The warrant expires five years from issuance.

## ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

### *CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS*

This Quarterly Report on Form 10-Q of Pressure BioSciences, Inc. ("PBI", "we", "us", "our", "the Company") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, forward-looking statements are identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. Such statements include, without limitation, statements regarding:

- our need for, and our ability to raise, additional equity or debt financing on acceptable terms, if at all;
- our need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient additional financing;
- our belief that we have sufficient liquidity to finance normal operations;
- the options we may pursue in light of our financial condition;
- the amount of cash necessary to operate our business;
- the anticipated uses of grant revenue and the potential for increased grant revenue in future periods;
- our plans and expectations with respect to our continued operations;
- our belief that pressure cycling technology ("PCT") has achieved initial market acceptance in the mass spectrometry and other markets;
- the expected increase in the number of PCT and constant pressure based units installed and the increase in revenues from the sale of consumable products and extended service contracts;
- the expected development and success of new instrument and consumables product offerings;
- the potential applications for our instrument and consumables product offerings;
- the expected expenses of, and benefits and results from, our research and development efforts;
- the expected benefits and results from our collaboration programs, strategic alliances and joint ventures;
- our expectation of obtaining additional research grants from the government in the future;

our expectations of the results of our development activities funded by government research grants;

the potential size of the market for biological sample preparation;

general economic conditions;

the anticipated future financial performance and business operations of our company;

our reasons for focusing our resources in the market for genomic, proteomic, lipidomic and small molecule sample preparation;

the importance of mass spectrometry as a laboratory tool;

the advantages of PCT over other current technologies as a method of biological sample preparation in biomarker discovery, forensics, and histology and for other applications;

the capabilities and benefits of our PCT sample preparation system, consumables and other products;

our belief that laboratory scientists will achieve results comparable with those reported to date by certain research scientists who have published or presented publicly on PCT and our other products;

our ability to retain our core group of scientific, administrative and sales personnel; and

our ability to expand our customer base in sample preparation and for other applications of PCT and our other products.

These forward-looking statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements, expressed or implied, by such forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this Quarterly Report on Form 10-Q to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial and other results include those discussed in the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015. We qualify all of our forward-looking statements by these cautionary statements.

## **OVERVIEW**

We are focused on solving the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by scientists worldwide working in biological life sciences research. Sample preparation is a term that refers to a wide range of activities that precede most forms of scientific analysis. Sample preparation is often complex, time-consuming and, in our belief, one of the most error-prone steps of scientific research. It is a widely-used laboratory undertaking – the requirements of which drive what we believe is a large and growing worldwide market. We have developed and patented a novel, enabling technology platform that can control the sample preparation process. It is based on harnessing the unique properties of high hydrostatic pressure. This process, called PCT, uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels i.e., 45,000 pounds per square inch (“psi”) or greater to safely, conveniently and reproducibly control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

Our pressure cycling technology uses internally developed instrumentation that is capable of cycling pressure between ambient and ultra-high levels at controlled temperatures and specific time intervals, to rapidly and repeatedly control the interactions of bio-molecules, such as deoxyribonucleic acid (“DNA”), ribonucleic acid (“RNA”), proteins, lipids and small molecules. Our laboratory instrument, the Barocycler<sup>®</sup>, and our internally developed consumables product line, which include our Pressure Used to Lyse Samples for Extraction (“PULSE”) tubes, and other processing tubes, and application specific kits such as consumable products and reagents, together make up our PCT Sample Preparation System (“PCT SPS”).

We have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of September 30, 2016, we did not have adequate working capital resources to satisfy our current liabilities and as a result we have substantial doubt about our ability to continue as a going concern. Based on our current projections, including equity financing subsequent to September 30, 2016, we believe we will have the cash resources that will enable us to continue to fund normal operations into the foreseeable future.

We need substantial additional capital to fund normal operations in future periods. If we are able to obtain additional capital or otherwise increase our revenues, we may increase spending in specific research and development applications and engineering projects and may hire additional sales personnel or invest in targeted marketing programs. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.

We hold 14 United States and 10 foreign patents covering multiple applications of PCT in the life sciences field. Our pressure cycling technology employs a unique approach that we believe has the potential for broad use in a number of established and emerging life sciences areas, including;

sample preparation for genomic, proteomic, and small molecule studies;

pathogen inactivation;

protein purification;

control of chemical (particularly enzymatic) reactions; and

immunodiagnostics (clinical laboratory testing).



We reported a number of accomplishments in the first nine months of 2016:

On January 12, 2016 SCIEX, a global leader in life science analytical technologies (Framingham, MA) and a wholly-owned subsidiary of Danaher Corporation (NYSE: DHR), announced an exclusive co-marketing agreement with PBI to improve protein quantification in complex samples.

On January 28, 2016 in a report focused on the exclusive co-marketing agreement between SCIEX and PBI, Emerging Growth LLC indicated the combination of the two company's technologies could result in superior biological insights and discoveries and in rapid and dramatic revenue growth for PBI.

On February 3, 2016 SCIEX and Children's Medical Research Institute (Sydney, Australia) announced they had joined forces to advance the promise of precision medicine. The partners stated they would benefit from SCIEX's exclusive collaborators, including Pressure BioSciences, and PBI's PCT platform for increased protein quantitation and reproducibility.

On March 14, 2016 the Company announced that we would participate in a SCIEX workshop on new innovations towards industrialized proteomics at the US HUPO scientific conference in Boston.

On April 12, 2016, the Company announced that we had been added to the high-performing Richmond Club Index. The Richmond Index has outperformed the S&P 500 Index by an average of 11% each year for the past ten years.

On July 13, 2016, the Company announced the unveiling of the newest addition to our product line based on their patented and powerful PCT platform, the Barocycler 2320EXTREME ("2320EXT"). The product unveiling took place during the recent annual conference of the American Society for Mass Spectrometry ("ASMS") in San Antonio, Texas.

On July 21, 2016, the Company announced the initial shipment of our Barocycler 2320EXTREME instrument to an Australian cancer research group (ProCan) named by the White House as a collaborator in the U.S.'s "Cancer Moonshot" initiative.

On October 26, 2016, the Company announced its featured participation in the recent opening of The ACRF International Centre for the Proteome of Human Cancer located in newly renovated laboratory facilities at the Children's Medical Research Institute near Sydney, Australia.

## Results of Operations

### *Comparison for the three months ended September 30, 2016 and 2015*

#### *Revenue*

We recognized total revenue of \$535,334 for the three months ended September 30, 2016 as compared to \$580,334 during the three months ended September 30, 2015, a decrease of \$45,000 or 8%. This decrease is solely attributable to decreases in grant related activities and technical support services as detailed below.

*Products, Services, Other.* Revenue from the sale of products and services increased 4% to \$500,949 for the three months ended September 30, 2016 as compared to \$481,452 during the three months ended September 30, 2015. This increase was primarily attributable to the launch of the Barocyler 2320 Extreme pressure-based instrument systems. Sales of consumables also increased for the three months ended September 30, 2016 to \$32,811 compared to \$28,339 during the same period in the prior year, an increase of 16%.

*Grant Revenue.* During the three months ended September 30, 2016, we recorded grant revenue of \$34,385 compared to grant revenue of \$98,882 in the comparable period in 2015. Work on the \$1.05 million NIH grant decreased during the third quarter as we continued to wait for certain significant parts to be manufactured. These parts were received during the second quarter of 2016, and are currently being put through our quality control procedures. Once released from quality control, the availability of these parts should result in an increase in grant work in future periods.

#### *Cost of Products and Services*

The cost of products and services was \$262,894 for the three months ended September 30, 2016 compared to \$209,804 for the comparable period in 2015. Gross profit margin on products and services was 47% for the three months ended September 30, 2016, as compared to 56% for the prior period. Cost of products increased and gross profit margin decreased because we sold several of our new Barocyler 2320EXTREME units during the quarter and the cost to manufacture these units was higher than expected because of start-up costs related to the initial manufacture of these systems. We expect the cost to manufacture these units will decrease and the sales price to increase in the coming quarters..

*Research and Development*

Research and development expenditures were \$268,317 during the three months ended September 30, 2016 as compared to \$355,574 in the same period in 2015, a decrease of \$87,257 or 25%. The prior period included the cost of research performed by a customer on our behalf.

Research and development expense recognized in the three months ended September 30, 2016 and 2015 included \$14,735 and \$18,307 of non-cash, stock-based compensation expense, respectively.

*Selling and Marketing*

Selling and marketing expenses increased to \$224,380 for the three months ended September 30, 2016 from \$207,888 for the comparable period in 2015, an increase of \$16,492 or 8%. This increase was due to commissions paid to our sales person and the cost of part-time help over the summer months in 2016.

During the three months ended September 30, 2016 and 2015, selling and marketing expense included \$9,911 and \$13,310 of non-cash, stock-based compensation expense, respectively.

*General and Administrative*

General and administrative costs totaled \$231,550 for the three months ended September 30, 2016 as compared to \$497,796 for the comparable period in 2015. This decrease was due primarily to credits received from charges incurred with a former professional service provider.

During the three months ended September 30, 2016 and 2015, general and administrative expense included \$65,854 and \$43,247 of non-cash, stock-based compensation expense, respectively.

*Operating Loss*

Our operating loss was \$451,807 for the three months ended September 30, 2016 as compared to \$690,728 for the comparable period in 2015, a decrease of \$238,921. This decrease was due primarily to credits received from a former professional service provider.

*Other Income (Expense), Net*

*Interest (Expense) Income*

Interest expense was \$1,116,328 for the three months ended September 30, 2016 as compared to interest expense of \$1,584,830 for the three months ended September 30, 2015. Interest expense primarily relate to debt discounts from the sale of senior secured convertible debentures and other convertible and non-convertible notes.

*Change in fair value of warrant derivative liability*

During the three months ended September 30, 2016, we recorded non-cash income of \$227,131 for warrant revaluation in our condensed consolidated statements of operations due to a decrease in the fair value of the warrant liability related to warrants issued in our private placement offerings. This decrease in fair value was primarily due to lower volatility in the price of the Company's common stock at September 30, 2016 as compared to the price on June 30, 2016. The components for determining the fair value of the warrants are contained in the table in Note 4 of the

accompanying condensed consolidated financial statements.

*Change in fair value of conversion option liability*

During the three months ended September 30, 2016, we recorded non-cash income of \$395,997 for conversion option revaluation in our condensed consolidated statements of operations due to a decrease in the fair value of the conversion option liability related to convertible debt. This decrease in fair value was primarily due to lower volatility in the price of the Company's common stock at September 30, 2016 as compared to the price on June 30, 2016 or the date the debt was incurred during the quarter and the shorter time to maturity of the debt. The components for determining the fair value of the conversion option liabilities are contained in the table in Note 4 of the accompanying condensed consolidated financial statements.

*Other Expense*

We had minimal other expenses for the three months ended September 30, 2016 and zero for the comparable period in 2015.

*Net Loss Applicable to Common Shareholders*

During the three months ended September 30, 2016, we recorded a net loss to common shareholders of \$945,207 or \$(0.03) per share, as compared to a net loss to common shareholders of \$656,217 or \$(0.03) per share in the three months ended September 30, 2015. The weighted average common shares outstanding for the period increased because of the issuance of shares of common stock to investor relations firms for services rendered and sales of common stock.

*Comparison for the nine months ended September 30, 2016 and 2015*

*Revenue*

We recognized total revenue of \$1,556,776 for the nine months ended September 30, 2016 as compared to \$1,433,572 during the nine months ended September 30, 2015, an increase of \$123,204 or 9%. This increase is attributable to increases in the sales of our products and services as detailed below.

*Products, Services, Other.* Revenue from the sale of products and services increased 22% for the nine months ended September 30, 2016 as compared to the year-earlier period from \$1,174,391 to \$1,429,487. This increase was primarily attributable to sales of the NEP2320 Enhanced Barocycler and the launch and subsequent sale of the Barocycler 2320EXTREME PCT-based instrument systems. Sales of consumables also increased for the nine months ended September 30, 2016 compared to the year-earlier period, from \$124,687 to \$149,819, an increase of 20%.

*Grant Revenue.* During the nine months ended September 30, 2016, we recorded grant revenue of \$127,289 compared to grant revenue of \$259,181 in the comparable period in 2015. Work on the \$1.05 million NIH grant decreased during the first half of 2016 as we needed to wait for certain significant parts to be manufactured. These parts were received during the second quarter of 2016, which should result in an increase in grant work in future periods.

*Cost of Products and Services*

The cost of products and services was \$727,698 for the nine months ended September 30, 2016 compared to \$575,780 for the comparable period in 2015. Gross profit margin on products and services was 49% for the nine months ended September 30, 2016, as compared to 51% for the prior period. Cost of products increased concomitant with the increase in product sales recorded for the period.

*Research and Development*

Research and development expenditures were \$925,015 during the nine months ended September 30, 2016 as compared to \$878,899 in the same period in 2015, an increase of \$46,116 or 5%. This increase resulted primarily from the addition of a Ph.D. level electrical engineer, costs related to the continued development of an enhanced rape kit test based on the PCT Platform, and a rent increase related to the additional R&D space.

Research and development expense recognized in the nine months ended September 30, 2016 and 2015 included \$50,766 and \$41,172 of non-cash, stock-based compensation expense, respectively.

*Selling and Marketing*

Selling and marketing expenses increased to \$609,501 for the nine months ended September 30, 2016 from \$574,289 for the comparable period in 2015, an increase of \$35,212 or 6%. This increase is primarily attributed to an increase in part-time employee related costs over the summer and holiday periods.

During the nine months ended September 30, 2016 and 2015, selling and marketing expense included \$32,404 and \$27,386 of non-cash, stock-based compensation expense, respectively.

*General and Administrative*

General and administrative costs totaled \$1,853,010 for the nine months ended September 30, 2016 as compared to \$2,034,040 for the comparable period in 2015. This decrease was due primarily to credits received from charges incurred with a former professional service provider.

During the nine months ended September 30, 2016 and 2015, general and administrative expense included \$199,641 and \$116,812 of non-cash, stock-based compensation expense, respectively.

*Operating Loss*

Our operating loss was \$2,558,448 for the nine months ended September 30, 2016 as compared to \$2,629,436 for the comparable period in 2015. This decrease was primarily due to credits from a former professional services provider offset by research and development and investor relations activities.

*Other Income (Expense), Net*

*Interest (Expense) Income*

Interest expense was \$2,961,708 for the nine months ended September 30, 2016 as compared to interest expense of \$2,831,106 for the nine months ended September 30, 2015. Interest expense primarily relate to debt discounts from the sale of senior secured convertible debentures and other convertible and non-convertible notes.

*Change in fair value of warrant derivative liability*

During the nine months ended September 30, 2016, we recorded non-cash income of \$59,864 for warrant revaluation in our consolidated statements of operations due to an overall decrease in the fair value of the warrant liability related to warrants issued in our private placement offerings. The components for determining the fair value of the warrants are contained in the table in Note 4 of the accompanying condensed consolidated financial statements.

*Change in fair value of conversion option liability*

During the nine months ended September 30, 2016, we recorded non-cash charges of \$472,364 for conversion option revaluation in our condensed consolidated statements of operations due to increases in the fair value of the conversion option liability related to convertible debt. We recorded \$1,337,510 as non-cash charge at issuance of these convertible debentures. The components for determining the fair value of the conversion option liabilities are contained in the table in Note 4 of the accompanying condensed consolidated financial statements.

*Other Expense*



Other Expense totaled \$1,112 for the nine months ended September 30, 2016 as compared to \$513,352 for the comparable period in 2015. The prior period activity represented revaluations for conversion options.

*Net Loss Applicable to Common Shareholders*

During the nine months ended September 30, 2016, we recorded a net loss to common shareholders of \$5,933,768 or (\$0.23) per share as compared to a net loss to common shareholders of \$3,451,928 or \$(0.17) per share in the nine months ended September 30, 2015. The weighted average common shares outstanding for the period increased because of the issuance of shares of common stock to investor relations firms for services rendered and conversions of Series K preferred stock into common stock.

*Liquidity and Financial Condition*

We have experienced negative cash flows from operations with respect to our pressure cycling technology business since our inception. As of September 30, 2016, we did not have adequate working capital resources to satisfy our current liabilities and as a result, we have substantial doubt regarding our ability to continue as a going concern. We have been successful in raising cash through debt and equity offerings in the past and as described in Note 6 to our unaudited consolidated financial statements for the three and nine months ended September 30, 2016, we completed an over-subscribed \$5 million debt financing on March 21, 2016, raising a total of \$6.3 million between July 2015 and March 2016. We have efforts in place to continue to raise cash through debt and equity offerings.

We will need substantial additional capital to fund our operations in future periods. In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects.

Net cash used in operations for the nine months ended September 30, 2016 was \$2,737,516 as compared to \$2,679,949 for the nine months ended September 30, 2015. The increase in cash used in operations in 2016 is principally due to the interest expense from the senior convertible debentures.

Cash used in investing activities for the nine months ended September 30, 2016 and 2015 was not significant.

Net cash provided by financing activities for the nine months ended September 30, 2016 was \$2,665,945 as compared to \$2,289,538 for the same period in the prior year. The cash from financing activities in the period ending September 30, 2016 included \$2,102,382 from senior secured convertible debt. We also received \$865,150 from non-convertible debt, net of fees, less payment on non-convertible debt of \$781,221. In the prior year we received \$3,991,437 from convertible debt and \$1,300,000 in proceeds from non-convertible debt.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

This Item 3 is not applicable to us as a smaller reporting company and has been omitted.

### **ITEM 4. CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act of 1934 filings are recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management was necessarily required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As of September 30, 2016, we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were not effective.

Our conclusion that our disclosure controls and procedures were not effective as of September 30, 2016 is due to the continued presence of the material weaknesses in our internal control over financial reporting identified in our Annual Report on Form 10-K for the year ended December 31, 2015. These material weaknesses are the following:

We identified a lack of sufficient segregation of duties. Specifically, this material weakness is such that the design over these areas relies primarily on detective controls and could be strengthened by adding preventative controls to properly safeguard Company assets.

Management has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles, particularly as it relates to valuation of warrants and other complex debt /equity transactions. Specifically, this material weakness resulted in audit adjustments to the annual consolidated financial statements and revisions to related disclosures, valuation of warrants and other equity transactions.

Limited policies and procedures that cover recording and reporting of financial transactions.

We continue to plan to remediate those material weaknesses as follows:

Improve the effectiveness of the accounting group by augmenting our existing resources with additional consultants or employees to assist in the analysis and recording of complex accounting transactions, and to simultaneously achieve desired organizational structuring for improved segregation of duties. We plan to mitigate this identified deficiency by hiring an independent consultant once we generate significantly more revenue or raise significant additional working capital.

Improve expert review and achieve desired segregation procedures by strengthening cross approval of various functions including quarterly internal audit procedures where appropriate.

During the period covered by this Report, we implemented and performed additional substantive procedures, such as supervisory review of work papers and consistent use of financial models used in equity valuations, to ensure our condensed consolidated financial statements as of and for the three month and nine month period ended September 30, 2016, are fairly stated in all material respects in accordance with GAAP. We have not, however, been able to fully remediate the material weaknesses due to our limited financial resources. Our remediation efforts are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

Except as described above, there have been no changes in our internal controls over financial reporting that occurred during the period ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 1. Legal Proceedings**

We are not currently involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our company or any of our subsidiaries, threatened against or affecting our company, our common stock, any of our subsidiaries or of our companies or our subsidiaries' officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

### **Item 1A. Risk Factors**

Factors that could cause or contribute to differences in our future financial and operating results include those discussed in the risk factors set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2015. The risks described in our Form 10-K and this Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on the Company. If any of the risks actually occur, our business, results of operations, cash flows or financial condition could suffer.

There have been no material changes to the risk factors set forth in Item 1 of our Annual Report on Form 10-K for the year ended December 31, 2015.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

Please refer to Note 6 to our unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2016, Convertible Debt and Other Debt, for a discussion of the sale of unregistered securities that took place for the quarter ended September 30, 2016.

In addition, on various dates from January to September 2016 the Company issued 755,000 shares of restricted common stock to investor relations firms for services rendered.

On August 29, September 9 and September 14, 2016, we completed three tranches of a private placement (the “Fall 2016 Private Placement”), pursuant to which we sold an aggregate of 1,125,000 shares of common stock, \$0.01 par value (the “Shares”), for a purchase price of \$0.40 per share, resulting in gross proceeds to us of approximately \$450,000 . The Shares were issued and sold to a total of 2 accredited investors pursuant to a Securities Purchase Agreement entered into as of the date of their investments. The investors received warrants to purchase a total of 1,125,000 shares of the Company’s common stock at an exercise price of \$0.50. The warrants expire 5 years after issuance.

The above securities were issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exemption from registration set forth in Rule 506 of Regulation D (“Regulation D”) promulgated under the Securities Act. We based such reliance upon representations made by each purchaser of the securities, including, but not limited to, representations as to the purchaser’s status as an “accredited investor” (as defined in Rule 501(a) under Regulation D) and the purchaser’s investment intent. The securities were not offered or sold by any form of general solicitation or general advertising, as such terms are used in Rule 502 under Regulation D. The securities may not be offered or sold in the United States absent an effective registration statement or an exemption from the registration requirements under applicable federal and state securities laws.

On October 11 and November 10, 2016, we completed two additional tranches of the Fall 2016 Private Placement, pursuant to which we sold an aggregate of 400,000 shares of common stock, \$0.01 par value (the “Shares”), for a purchase price of \$0.40 per share, resulting in gross proceeds to us of approximately \$160,000. The Shares were issued and sold to a total of 2 accredited investors pursuant to a Securities Purchase Agreement entered into as of the date of their investments. The investors received warrants to purchase a total of 400,000 shares of the Company’s common stock at an exercise price of \$0.50. The warrants expire 5 years after issuance.

### **Item 3. Defaults upon Senior Securities**

None.

### **Item 4. Mine Safety Disclosures**

Not applicable.

### **Item 5. Other Information**

None.

29

**Item 6. Exhibits**

**Exhibits**

- 4.1 Common Stock Purchase Warrant
- 10.1 Securities Purchase Agreement
- 31.1 Principal Executive Officer and Principal Financial Officer Certification Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1\* Principal Executive Officer and Principal Financial Officer Certification Pursuant to Item 601(b)(32) of Regulation S-K, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 101.INS XBRL Instance Document
- 101.SCH XBRL Taxonomy Extension Schema Document
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

\* In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are furnished and not filed.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**PRESSURE BIOSCIENCES, INC.**

Date: November 14, 2016 By: */s/ Richard T. Schumacher*  
Richard T. Schumacher  
President & Chief Executive Officer  
(Principal Executive Officer and Principal Financial Officer)

